A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Multiple Doses of Quinidine Sulfate, a P-glycoprotein (P-gp) Inhibitor, on the Pharmacokinetics of Nalbuphine Extended-Release Tablets in Healthy Adult Subjects
Trevi Therapeutics
Summary
The primary purpose of this study is to evaluate the effect of quinidine sulfate on the pharmacokinetics (PK) of NAL ER in healthy participants.
Eligibility
- Age range
- 18–60 years
- Sex
- All
- Healthy volunteers
- Yes
Key Inclusion Criteria: * Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kilogram per meter square (kg/m\^2) at screening. * Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms (ECGs), as deemed by the principal investigator (PI) or designee. Exclusion Criteria: * History of any diagnosed moderate or severe substance use disorder, other than tobacco use disorder, or a history of or current regular excessive consumption of alcohol. * Positive urine drug or alcohol results. * Smoker who has smoked or used nico…
Interventions
- DrugNAL ER
Oral tablets
- DrugQuinidine Sulfate
Oral tablets
Location
- Clinical Pharmacology of Miami, LLCMiami, Florida